medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 6

<< Back Next >>

Gac Med Mex 2003; 139 (6)

The Clinical Importance of Insulin-Like Growth Factors

Leal-Guadarrama LI, Ochoa-Rojas MC, Méndez JD

Language: Spanish
References: 70
Page: 589-599
PDF size: 102.40 Kb.


ABSTRACT

Objective: To review the physiologic role of IGFs and impact in the clinical area. Materials: We carried out a search in MEDLINE and INDEX MEDICUS from 1995 to 2000 and relevant articles were selected. Results: IGFs are polypeptides involved in cellular development and growth. Their structure is similar to proinsulin. The biological effects of IGFs are produced when they bind their receptors. The majority of circulating IGFs are bound to specific proteins called IGFBPs that modulate the effects of IGFs. Imbalance in IGF-IGFBP production is associated with several pathological conditions. Conclusions: Several studies have demonstrated that administration of IGFs may be a promissory treatment for certain diseases related not only to growth, but also to diabetes mellitus, hyperinsulinism and some cardiopathies.


REFERENCES

  1. Job JC, Pierson M. Endocrinología pediátrica y crecimiento. España: Editorial Científico-Médica.1983.

  2. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253(8):2769-2776.

  3. Rinderknecht E, Humbel RE. Primary structure of human insulin-like growth factor II. FEBS Lett 1978;89(2):283-286.

  4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins:biological actions. Endocr Rev 1995;16(1):3-25.

  5. Froesch ER, Schmid Ch, Schwander J, Zapf J. Actions of insulin-like growth factors. Ann Rev Physiol 1995;47:443-67.

  6. Werner H, Adamo M, Roberts CT, Leroith D. Molecular and cellular aspects of insulin-like growth factor action. Vitam Horm 1994;48:1-39.

  7. Styne D. Growth. In: Basic and clinical endocrinology. 5th ed. Greenspan FS, Strewler GJ, editors. Appleton & Lange. USA: 1997. p. 157-181.

  8. Kong W, Philipps AF, Dvorak B, Anderson GG, Lake M, Koldovsky O. Presence of insulin-like growth factor I but absence of the binding proteins in the bile of rats. Am J Physiol 1995;268(1 Pt 2):R266-R271.

  9. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15(1):80-95.

  10. Nonoshita LD, Wathen NC, Dsupin BA, Chard T, Giudice LC. Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and proteolyzed IGFBP-3 in embryonic cavities in early human pregnancy: their potential relevance to maternal-embryonic and fetal interactions. J Clin Endocrinol Metab 1994;79(5):1249-1255.

  11. Calvo EL, Bernatchez G, Pelletier G, Iovanna JL, Morisset J. Downregulation of IGF-I mRNA expression during postnatal pancreatic development and overexpression after subtotal pancreatectomy and acute pancreatitis in the rat pancreas. J Mol Endocrinol 1997;18(3):233-42.

  12. Jubiz W. Endocrinología clínica. 3a. ed. Manual Moderno. México: 1996. p. 13.

  13. Wang SN, Lapage J, Hirschberg R. Glomerular ultrafiltration of IGF-I may contribute to increased renal sodium retention in diabetic nephropathy. J Lab Clin Med 1999;134(2):154-60.

  14. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor 1 rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treatment 1999;56(1):1-10.

  15. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999. 31(11):2049-61.

  16. Rechler MM, Nissley SP. The nature and regulation of the receptors for insulin-like growth factors. Ann Rev Physiol 1985;47:425-42.

  17. Gourmelen M, Perin L, Le Bouc Y. IGFs and their binding proteins. Nucl Med Biol 1994;21(3):297-302.

  18. Smith WJ, Jeong Nam T, Underwood LE, Busby WH, Celnicker A, Clemmons DR. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993;77(5):1294-1298.

  19. Magee BA, Shooter GK, Wallace JC, Francis GL. Insulin-like growth factor 1 and its binding proteins: a study of the binding interface using B-domain analogues. Biochemistry 1999; 38(48):15863-70.

  20. Giudice LC. Editorial: IGF binding protein-3 protease regulation: how sweet it is! J Clin Endocrinol Metab 1995; 80(8):2279-2281.

  21. Clemmons D. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998;140:19-24.

  22. Camacho-Hubner C, Busby W, McCusker R, Wright G, Clemmons D. Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J Biol Chem 1992;267(17):11949-11956.

  23. Juul A, Dalgaard P, Blum WG, Bang P, Hall K, Michaelsen KF, Muller J, Skakkebaek NE. Serum levels of insulin-like growth factor (IGF)-binding protein-s (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-1, IGF-2, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80(8):2534-2542.

  24. Rosenfeld R, Pham H, Oh Y, Lamson G, C Giudice L. Identification of insulin-like growth factor-binding protein-2 (IGF-BP-2) and a low molecular weight IGF-BP in human seminal plasma. J Clin Endocrinol Metab 1990;70(2):551-553.

  25. Nogami H, Watanabe T, Kobayashi S. IGF-I and IGF-binding protein gene expressions in spontaneous dwarf rat. Am J Physiol 1994;267(Endocrinol Metab 30):E396-E401.

  26. Bereket A, Lang Ch H, Blethe S, Fan J, Rost RA, Wilson TA. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995;80(8):2282-2287.

  27. Huang YS, Rousseau K, Le Belle N, Vidal B, Burzawa-Gerard E, Marchelidon J, Dufour S. Insulin-like growth factor-1 stimulates gonadotrophin production from eel pituitary cells: a possible metabolic signal for induction of puberty. J Endocrinol 1998;159(1):43-52.

  28. Luna AM, Wilson DM, Wibbelsman Ch J, Brown RC, Nagashima RJ, Hintz RL, Rosenfeld RG. Somatomedins in adolescence: a cross-sectional study of the effect of puberty on plasma insulin-like growth factor I and II levels. J Clin Endocrinol Metab 1983;57(1):268-271.

  29. Liu JL, LeRoith D. Insulin-like growth factor 1 is essential for postnatal growth in response to growth hormone. Endocrinology 1999;149(11):5178-84.

  30. Welle S. Growth hormone and insulin-like growth factor-1 as anabolic agents. Curr Opini Clini Nutr Metabolic Care 1998;1(3):257-62.

  31. Mandel S, Moreland E, Nichols V, Hanna CH, Lafranchi S. Changes in insulin-like growth factor 1 (IGF-I), IGF binding protein -3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment.J Clin Endocrinol Metab 1995;80(1):190-194.

  32. Span JP, Pieters GF, Sweep CG, Swinkels LM, Smals AG. Plasma IGF-I is a useful marker of growth hormone deficiency in adults. J Endocrinol Invest 1999. 22(6):446-50.

  33. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 1992;262(Endocrinol Metab 25):E130-E133.

  34. Zapf J. Growth promotion by insulin-like growth factor 1 in hypophysectomized and diabetic rats. Mol Cell Endocrinol 1998;140(1-2):143-9.

  35. Laron Z. The essencial role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 1999;84(12):4397-404.

  36. Mizuta Y, Isomoto H, Futuki Y, Ehara N, Takeshima F, Omagari K, Murase K, Yakata Y, Senjyu M, Masuda J, Ikuno N, Haraguchi M, Iwasaki K, Shimokawa I, Kohno S. Acinar cell carcinoma of the pancreas associated with hypoglycemia: involvement of "big" insulin-like growth factor-II. JGastroenterol 1998;33(5):761-5.

  37. Frystyk J, Skjaerbaek C, Zapf J, Orskov H. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetología 1998;41(5):589-94.

  38. Michell NP, Langman MJ, Eggo MC. Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 1997;76(1):60-6.

  39. Khandwala H, McCutcheon I, Flyvbjerg A, Friend K. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21(3):215-244.

  40. Fukasawa Y, Takada A, Sato H, Koizumi M, Tanaka A, Sato T. Solitary fibrous tumor of the pleura causing recurrent hypoglycemia by secretion of insulin-lilke growth factor 2. Pathol Inter 1998;48(1):47-52.

  41. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-1 and serum IGF-binding protein 3 can ben-associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999;57(4):330-40.

  42. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000;43:1205-1223.

  43. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabet/Metabol Res Rev 1999;15(5):314-322.

  44. Horney MJ, Shirley DW, Kurtz DT, Rosenzweig SA. Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am J Physiol 1998;274(6 Pt 2):F1045-53.

  45. Brown DL, Kane CD, Chernausek SD, Greenhalgh DG. Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice. Am J Pathol 1997;151(3):715-24.

  46. Bach M, Chin E, Bondy C. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994;79(4):1040-1045.

  47. Janssen J, Jacobs ML, Derkx FH, Weber RF, Lely AJ, Lamberts SW. Free and total insulin-like growth factor I (IGF-I), IGF-binding proteín-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab1997;82(9): 2809-2815.

  48. Dills D, Allen C, Palta M, Zaccaro D, Klein R, D'Alessio D. Insulin-like growth factor-I is related to glycemic control in children and adolelscents with newly diagnosed insulin-dependent diabetes. J Clin Endocrinol Metab 1995;80(7):2139-2143.

  49. Landau D, Chin E, Bondy C, Domene H, Roberts Ch, Gronbaek H, Flyvbjerg A, Leroith D. Expression of insulin-like growth factor binding proteins in the rat kidney:effects of long-term diabetes. Endocrinology 1995;136(5):1835-1842.

  50. Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB. Effects of low-dose recombinant human insulin-llike growth factor -1 on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabol Clini Exp 1998; 47(12):1491-9.

  51. Tomas F, Knowles S, Owens P, Burgoyne J, Chandler C, Ballard J. Conjoint IGF-I and insulin infusion shows diverse interactive effects in diabetic rats. Diabetes1996;45:170-177.

  52. Carroll P, Umpleby M, Ward G, Imuere S, Alexander E, Dunger D, Sönksen P, Russell-Jones D. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 1997;46:1453-1458.

  53. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Inte 1998;63(2):107-11.

  54. Cheetham TD, Holly JM, Baxter RC, Meadows K, Jones J, Taylor AM, Dunger DB. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1998;157(1):81-7.

  55. Moses A, Young S, Morrow L, O'Brien M, Clemmons D. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes1996;45:91-100.

  56. Asada T, Ogawa T, Iwai M, Shimomura K, Kobayashi M. Recombinant insulin-like growth factor I normalizes expression of renal glucose transporters in diabetic rats. Am J Physiol 1997;273(Renal Physiol 42):F27-F37.

  57. Levitt K L, Ferry R, Stanley C, Collett-Solberg P, Baker L, Cohen P. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective b-cell sulfonylurea receptor. J Clin Endocrinol Metab 1999;84(9):3117-3124.

  58. Zhang Q, Berggren PO, Larsson O, Hall K, Tally M. Insulin-like growth factor II inhibits glucose-induced insulin exocytosis. Biochem Biophys Res Commun 1998;243(1):117-21.

  59. Katz LE, Ferry RJ JR, Stanley CA, Collett-Solberg PF, Baker L, Cohen P. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor 1 in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor. J Clin Endocrinol Metab 1999;84(9):3117-24.

  60. Boonen S, Mohan S, Dequeker J. Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ. Down-regulation of the serum stimulatory components ot the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein 3 and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 1999;14(12):2150-8.

  61. Park MJ, Kim HS, Kang JH, Kim DH, Chung CY. Serum levels of insulin-like growth factor (IGF-I), free IGF-I, IGF binding protein (IGFBP-1, IGFBP-3) and insulin in obese children. J Pediatr Endocrinol Metab 1999;12(2):139-144.

  62. Radetti G, Bozzola M, Pasquino B, Paganini C, Aglialoro A, Livieri C, Barreca A. Growth hormone bioactivity, insulin-like growth factors and IGF binding proteins in obese children. Metabolism 1998;47(12):1490-1493.

  63. Le Roith D, Bondy C, Yakar S, Liu J, Butler A. The somatomedin hypothesis:2001. Endocr Rev 2001;22(1):53-74.

  64. Nogowsky L, Nowak KW. Arginine, administered in various ways, as a stimulator of insulin secretion in the rabbit. Horm Metab Res 1986;18:730-733.

  65. Lockwood DH, Lipsky JJ, Meronk F, East LE. Actions of polyamines on lipid and glucose metabolism of fat cells. Biochem Biophys Res Commun 1971;44:600-607.

  66. Hougard DM, Nielsen JH, Larson LI. Localization and biosynthesis of polyamines in insulin-producing cells. Biochem J 1986;238:43-47.

  67. Sjöholm A. Effects of secretagogues on insulin biosynthesis and secretion in polyamine-depleted pancreatic ?-cells. Am J Physiol 1988;270 (Cell Physiol 39)C1105-C1110.

  68. Méndez JD, Arreola MA. Effect of L-arginine on pancreatic arginase activity and polyamines in alloxan treated rats. Biochem Int 1992;28:569-575.

  69. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-1172.

  70. Méndez JD, Balderas F. Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in diabetic rats. Biochimie 2001;83:453-458.




2020     |     www.medigraphic.com